Globus Medical, Inc.

- No indication of new fundraising through debt or equity in the current quarter. - Company has $799.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026. - Existing share repurchase program of $500 million initiated in Q2 2025; $110 million purchased so far with $390 million remaining. - Capital allocation priorities include internal investment in product development, supporting sales force expansion, manufacturing investments, share repurchases, and evaluating complementary M&A. - No new debt issuance mentioned; paydown of $450 million convertible debt occurred in Q1 2025. - Focus remains on organic growth and strategic uses of capital rather than new debt or equity fundraising at this time.

- Capital expenditures were $39.6 million in the recent quarter, representing 5.2% of sales. - Capital allocation priorities remain: - Internal investment in innovative product development. - Capital spending on building sets for global sales force. - Investments in facilities, machinery, and equipment to expand manufacturing footprint. - Continued share repurchase program with $390 million remaining authorized as of March 31, 2026. - Ongoing evaluation of complementary M&A focused on investments driving long-term profitable growth. - Increased focus on R&D spending, especially doubled investment in Spine and Enabling Technologies. - Emphasis on supply chain initiatives to improve cost efficiency and support margin expansion.

- U.S. Spine business expected to continue strong growth, with recent quarters showing around 10% growth, driven mainly by market share gains. - International Spine business targeting a return to consistent low double-digit growth (around 10% constant currency), with mid-teens growth seen recently influenced by currency and prior-year supply chain disruptions. Long term, international growth expected in the low to mid-double-digit range (12%-15%), focusing on deeper market penetration rather than expanding into new countries. - Enabling Technologies business growing, with 21% revenue increase in Q1 2026, but shifting to more flexible offerings (leases/rentals) possibly moderating upfront revenue recognition. - Trauma and neuromonitoring businesses showing strong growth (over 30%). - Overall guidance for 2026 revenue reaffirmed at $3.18B to $3.22B, implying 8.2% to 9.6% growth over 2025. - Long-term goal is sustainable, profitable growth supported by innovation, increased R&D, and operational efficiencies.

- Globus Medical reiterated full-year 2026 revenue guidance of $3.18 billion to $3.22 billion, implying 8.2% to 9.6% growth over 2025. - Non-GAAP diluted EPS guidance was raised to $4.70 to $4.80 from $4.40 to $4.50, implying 18.1% to 20.6% growth over 2025. - EPS growth is driven by margin expansion (gross profit margin sustained above 69% in Q1) and operating leverage from sales growth. - Management expects continued gross margin improvements, targeting mid-70% gross margin long term with ongoing supply chain and manufacturing initiatives. - While top-line growth is expected at high single digits long-term, bottom-line (EPS) growth is expected to outpace revenue growth. - R&D spending will increase, especially in Spine and Enabling Technologies, which may modestly offset some margin gains. - No specific 2027 guidance is provided, but strategic focus remains on sustainable, profitable double-digit EPS growth.

The transcript does not provide explicit details on the current or expected orderbook or pending orders. However, relevant insights related to demand and sales outlook include: - The company is experiencing strong demand, with U.S. Spine and International Spine businesses growing well. - There is a focus on growing implant procedures driven by robotic system placements and training. - The Enabling Technology segment is shifting towards more rental/leasing models, which creates a larger pipeline but affects upfront revenue recognition. - Management emphasizes smart growth, going deeper into existing markets rather than expanding into new countries. - Despite competitive dynamics elongating deal cycles, Excelsius robotics remains well-positioned with unique technology. - No explicit quantitative order backlog or pending order numbers are disclosed on the call.